We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · June 29, 2020

QOL Data: Abemaciclib Plus an Aromatase Inhibitor in HR+, HER2− Advanced Breast Cancer

The Oncologist


Additional Info

Disclosure statements are available on the authors' profiles:

The Oncologist
Health-Related Quality of Life in MONARCH 3: Abemaciclib Plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast Cancer
Oncologist 2020 Jun 14;[EPub Ahead of Print], MP Goetz, M Martin, E Tokunaga, IH Park, J Huober, M Toi, C Stoffregen, S Shekarriz, V Andre, MC Gainford, GL Price, S Johnston

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading